$WVE News

Wells Fargo Maintains Overweight on WAVE Life Sciences, Raises Price Target to $14

HC Wainwright & Co. Maintains Buy on WAVE Life Sciences, Lowers Price Target to $13

Wave Life Sciences Ltd. (WVE) Shareholder/Analyst Call Transcript

Wave Life Sciences Ltd. (WVE) Shareholder/Analyst Call - Slideshow

Wave Life Sciences Announces Updated Data From Ongoing RestorAATion-2 Trial Of WVE-006, Investigational, GalNAc-Conjugated, Subcutaneously Delivered RNA Editing Oligonucleotide For Alpha-1 Antitrypsin Deficiency

Citigroup Maintains Buy on WAVE Life Sciences, Lowers Price Target to $24

Canaccord Genuity Maintains Buy on WAVE Life Sciences, Lowers Price Target to $43

Truist Securities Maintains Buy on WAVE Life Sciences, Lowers Price Target to $15

Wave Life Sciences (NASDAQ:WVE) Beats Q1 Estimates as Obesity Program Accelerates

Wave Life Sciences Reports Cash And Cash Equivalents Of $544.6M As Of March 31, 2026, With Expected Cash Runway into Q3 2028

Wave Life Sciences Reports Cash And Cash Equivalents Of $544.6M As Of March 31, 2026, With Expected Cash Runway into Q3 2028

WAVE Life Sciences Q1 EPS $(0.13) Beats $(0.33) Estimate, Sales $38.246M May Not Be Comparable To $9.119M Estimate

Wave Life Sciences Seeks Stockholders, Singapore High Court Approvals To Redomicile From Singapore To U.S.

Wave Life Sciences Board Approves Plan To Redomicile Parent Company Of Wave Life Sciences Group Of Companies From Singapore To US

HC Wainwright & Co. Maintains Buy on WAVE Life Sciences, Lowers Price Target to $18

Wave Life Sciences shares are trading higher after a Form 4 filing showed that a Director purchased 8.8 million shares at $6.23 per share on behalf of RA Capital Management.

Wave Life Sciences Ltd. (WVE) Discusses Positive Interim Phase I Data from INLIGHT Trial of WVE-007 for Obesity Transcript

B of A Securities Maintains Buy on WAVE Life Sciences, Lowers Price Target to $21

Wells Fargo Maintains Overweight on WAVE Life Sciences, Lowers Price Target to $13

Wave Life Sciences Ltd. (WVE) Discusses Positive Interim Phase I Data from INLIGHT Trial of WVE-007 for Obesity - Slideshow